Streetbeat News

Analyst Ratings

LLY

Eli Lilly & Co.'s experimental drug, retatrutide, has shown significant weight loss results in a mid-stage study, with most participants losing nearly a quarter of their body weight. The drug's effectiveness seems to stem from its unique approach to manipulating appetite-controlling hormones. Beyond weight loss, retatrutide has shown promising health impacts, such as a 20% reduction in LDL or “bad” cholesterol, and an over 80% decrease in liver fat levels.

Portfolio Pulse from Benzinga Newsbot

June 28, 2023 | 2:21 am

QQQ

SPY

Mohamed El-Erian, Allianz's chief economic adviser, has expressed confidence in the latest set of economic data, stating that there is no reason for the US to fall into recession. He highlighted the rise in The Conference Board Consumer Confidence Index and the upbeat housing market data. The Nasdaq Composite and the S&P 500 ended over 1% higher on Tuesday. The SPDR S&P 500 ETF Trust (NYSE:SPY) closed 1.1% higher while the Invesco QQQ Trust Series 1 (NASDAQ:QQQ) gained 1.72% on Tuesday.

Portfolio Pulse from Bhavik Nair

June 28, 2023 | 2:15 am

NVO

Aileen Lee, partner at Cowboy Ventures, likened the current fiscal tightening in Silicon Valley to the effects of the weight loss drug Ozempic, suggesting startups will need to 'do more with less and become healthier'. This comes in response to the capital challenges startups have faced since early 2022. Novo Nordisk (NASDAQ:NVO), the manufacturer of Ozempic, has seen a surge in demand for the drug due to its effectiveness in weight loss.

Portfolio Pulse from Benzinga Newsbot

June 28, 2023 | 1:13 am

GME

GameStop Corp (NYSE:GME) is analyzed as a compelling investment opportunity due to ventures into web3, NFTs, digital video game skins, strategic partnerships, financial stability, e-commerce growth, omnichannel integration, insider ownership, increased brand recognition, and exceptional stock performance. Partnerships with Loopring, Immutable X, and Microsoft are highlighted. Gamestop's stock performance has increased by 2,024% over the last three years, compared to the S&P 500's return of 42% during the same period.

Portfolio Pulse from Kevin Malone

June 27, 2023 | 9:45 pm

RBLX

Roblox Corp (NYSE:RBLX) is set to discuss its artificial intelligence (AI) initiatives with Morgan Stanley on Wednesday. The company previously highlighted its vision for the future of creation revolving around generative AI. Roblox believes that generative AI tools could help accelerate creator productivity and bring ideas to life. The company also recently announced a deeper push to appeal to the 17 and over crowd of gamers on its platform. Roblox shares were up 6.66% to $41.82 on Tuesday.

Portfolio Pulse from Chris Katje

June 27, 2023 | 9:22 pm

NTR

Unusual options activity has been observed for Nutrien (NYSE:NTR), with a large position indicating a bullish stance. The sentiment among these big-money traders is split between 58% bullish and 41% bearish. The options activity suggests a target price range of $45.0 to $75.0 for Nutrien. Current price of NTR is $59.09, down by 0.94%. Analysts from B of A Securities, Barclays, and Morgan Stanley have maintained their positive ratings on Nutrien with price targets of $85, $70, and $70 respectively.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:47 pm

CAT

A significant amount of unusual options activity has been observed for Caterpillar (NYSE:CAT), with a majority of investors taking a bullish stance. The trades indicate a target price range of $200 to $260 for Caterpillar over the next three months. The current price of CAT is up 1.58% at $240.69. DA Davidson has downgraded its action to Neutral with a price target of $263, while Tigress Financial maintains a Buy rating with a price target of $282.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:31 pm

CRWD

CrowdStrike Holdings (NASDAQ:CRWD) has seen unusual options activity, with a majority of investors taking a bearish stance. The price range targeted by whales over the last 3 months is from $65.0 to $190.0. The current price of CRWD is up 1.74% at $144.28. Analysts have mixed opinions, with Needham and UBS maintaining a Buy rating with a price target of $170, while Stifel maintains a Hold rating with a price target of $128.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 8:31 pm

JEF

Jefferies Financial Gr (NYSE:JEF) reported Q2 earnings of $0.05 per share, missing the analyst consensus estimate of $0.27 by 81.48%. This is a 88.89% decrease from the same period last year. The company's quarterly sales of $1.04 billion met the analyst consensus estimate, marking a 24.21% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 8:16 pm

FLGC

Flora Growth Corp. (NASDAQ:FLGC) has appointed Clifford Starke as CEO and Dany Vaiman as CFO. Starke, the former President of the company, replaces Hussein Rakine, who will remain on the board. Vaiman replaces Elshad Garayev, who will stay on as an advisor. The company also announced it has regained compliance with NASDAQ's minimum bid requirement. Starke believes the cannabis industry is at a critical juncture and sees potential for Flora to emerge as a premier international company.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 8:08 pm